Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1913031 | 0.93 | TSHR (0.40) | DAGLAALDH1A1HTT | |
| SCHEMBL648626 | 0.89 | PIN1 (0.38) | PIN1LPAR1LPAR5PLA2G4ADAGLA | |
| SCHEMBL1912873 | 0.89 | CRHR1 (0.39) | ALDH1A1 | |
| SCHEMBL650123 | 0.86 | C5AR1 (0.39) | DAGLAALDH1A1HTT | |
| SCHEMBL648961 | 0.84 | TLR7 (0.36) | ALDH1A1HTT | |
| SCHEMBL651033 | 0.84 | C5AR1 (0.44) | DAGLAALDH1A1HTT | |
| SCHEMBL1913047 | 0.84 | ALDH1A1 (0.36) | DAGLAALDH1A1HTT | |
| SCHEMBL651001 | 0.83 | CRHR1 (0.38) | PIN1LPAR1LPAR5 | |
| SCHEMBL5138076 | 0.83 | AGTR1 (0.36) | AGTR1AGTR2PIN1PLA2G4A | |
| SCHEMBL651956 | 0.83 | C5AR1 (0.43) | DAGLAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |